Author details

Full Name

John P Moore

Affiliation

ORCID

Career Start Year

1988

Papers

403

H Index

122

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37044090	Germline-targeting HIV-1 Env vaccination induces VRC01-class antibodies with rare insertions.	Cell Rep Med	2023
36334723	Longitudinal antibody response kinetics following SARS-CoV-2 messenger RNA vaccination in pregnant and nonpregnant persons.	American journal of obstetrics & gynecology MFM	2023
37903160	Glycan heterogeneity as a cause of the persistent fraction in HIV-1 neutralization.		2023
37244989	Conformational antigenic heterogeneity as a cause of the persistent fraction in HIV-1 neutralization.		2023
36865101	Conformational antigenic heterogeneity as a cause of the persistent fraction in HIV-1 neutralization.		2023
34669426	The Glycan Hole Area of HIV-1 Envelope Trimers Contributes Prominently to the Induction of Autologous Neutralization.	Journal of Virology	2022
35584627	Broad and ultra-potent cross-clade neutralization of HIV-1 by a vaccine-induced CD4 binding site bovine antibody.	Cell Reports Medicine	2022
35384694	Reappraising the Value of HIV-1 Vaccine Correlates of Protection Analyses.	Journal of Virology	2022
35932217	Asthma 17q21 polymorphism associates with decreased risk of COVID-19 in children.	Pediatric Pulmonology	2022
35677643	Structural dynamics reveal isolate-specific differences at neutralization epitopes on HIV Env.	iScience	2022
34531563	Beta testing the monkey model.	Nature Immunology	2021
33705704	Virus vaccines: proteins prefer prolines.		2021
33524125	Postconvalescent SARS-CoV-2 IgG and Neutralizing Antibodies are Elevated in Individuals with Poor Metabolic Health.	J Clin Endocrinol Metab	2021
33835558	Antimicrobial activity of fluoroquinolones.	Veterinary Record	2021
33515984	Testing-on-a-probe biosensors reveal association of early SARS-CoV-2 total antibodies and surrogate neutralizing antibodies with mortality in COVID-19 patients.	Biosensors and Bioelectronics	2021
34100023	Emerging SARS-CoV-2 variants of concern evade humoral immune responses from infection and vaccination.	medRxiv	2021
33662101	Approaches for Optimal Use of Different COVID-19 Vaccines: Issues of Viral Variants and Vaccine Efficacy.	JAMA - Journal of the American Medical Association	2021
33563983	Immunofocusing and enhancing autologous Tier-2 HIV-1 neutralization by displaying Env trimers on two-component protein nanoparticles.	npj Vaccines	2021
33608249	Immunogenicity of clinically relevant SARS-CoV-2 vaccines in nonhuman primates and humans.	Science advances	2021
33507218	SARS-CoV-2 Vaccines and the Growing Threat of Viral Variants.	JAMA - Journal of the American Medical Association	2021
33826885	Enhancing glycan occupancy of soluble HIV-1 envelope trimers to mimic the native viral spike.	Cell Reports	2021
34193339	Predictors of Nonseroconversion after SARS-CoV-2 Infection.	Emerg Infect Dis	2021
34136730	Antibody Responses to SARS-CoV-2 mRNA Vaccines Are Detectable in Saliva.	Pathog Immun	2021
33438580	High-resolution mapping of the neutralizing and binding specificities of polyclonal sera post-HIV Env trimer vaccination.	eLife	2021
33758842	Antibody responses to SARS-CoV-2 mRNA vaccines are detectable in saliva.	bioRxiv	2021
34404812	Interplay of diverse adjuvants and nanoparticle presentation of native-like HIV-1 envelope trimers.	npj Vaccines	2021
34516917	Emerging SARS-CoV-2 variants of concern evade humoral immune responses from infection and vaccination.	Sci Adv	2021
34728634	Author Correction: Interplay of diverse adjuvants and nanoparticle presentation of native-like HIV-1 envelope trimers.	npj Vaccines	2021
34390501	Serologic response to mRNA COVID-19 vaccination in lymphoma patients.	Am J Hematol	2021
34432859	Antibody responses induced by SHIV infection are more focused than those induced by soluble native HIV-1 envelope trimers in non-human primates.	PLoS Pathogens	2021
34376662	Polyclonal antibody responses to HIV Env immunogens resolved using cryoEM.	Nat Commun	2021
32999024	Neutralizing Antibody Responses Induced by HIV-1 Envelope Glycoprotein SOSIP Trimers Derived from Elite Neutralizers.	Journal of Virology	2020
32393800	T cell-inducing vaccine durably prevents mucosal SHIV infection even with lower neutralizing antibody titers.	Nat Med	2020
32272076	Env Exceptionalism: Why Are HIV-1 Env Glycoproteins Atypical Immunogens?		2020
33521696	Convalescent plasma-mediated resolution of COVID-19 in a patient with humoral immunodeficiency.	Cell Rep Med	2020
32591466	COVID-19 Vaccines: "Warp Speed" Needs Mind Melds, Not Warped Minds.	Journal of Virology	2020
32748788	Tailored design of protein nanoparticle scaffolds for multivalent presentation of viral glycoprotein antigens.	Elife	2020
33236020	Testing-on-a-probe biosensors reveal association of early SARS-CoV-2 total antibodies and surrogate neutralizing antibodies with mortality in COVID-19 patients.		2020
32573433	Antibodies to SARS-CoV-2 and their potential for therapeutic passive immunization.	eLife	2020
30770829	Capturing the inherent structural dynamics of the HIV-1 envelope glycoprotein fusion peptide.	Nat Commun	2019
31619555	SOS and IP Modifications Predominantly Affect the Yield but Not Other Properties of SOSIP.664 HIV-1 Env Glycoprotein Trimers.	Journal of Virology	2019
30487280	Closing and Opening Holes in the Glycan Shield of HIV-1 Envelope Glycoprotein SOSIP Trimers Can Redirect the Neutralizing Antibody Response to the Newly Unmasked Epitopes.	J Virol	2019
31142746	Structure and immunogenicity of a stabilized HIV-1 envelope trimer based on a group-M consensus sequence.	Nat Commun	2019
31537780	Enhancing and shaping the immunogenicity of native-like HIV-1 envelope trimers with a two-component protein nanoparticle.	Nat Commun	2019
30958859	Optimizing the production and affinity purification of HIV-1 envelope glycoprotein SOSIP trimers from transiently transfected CHO cells.	PLoS ONE	2019
30728245	Stabilization of the V2 loop improves the presentation of V2 loop-associated broadly neutralizing antibody epitopes on HIV-1 envelope trimers.	J Biol Chem	2019
30776383	Developability Assessment of Physicochemical Properties and Stability Profiles of HIV-1 BG505 SOSIP.664 and BG505 SOSIP.v4.1-GT1.1 gp140 Envelope Glycoprotein Trimers as Candidate Vaccine Antigens.	Journal of Pharmaceutical Sciences	2019
31194940	Conformational Plasticity in the HIV-1 Fusion Peptide Facilitates Recognition by Broadly Neutralizing Antibodies.	Cell Host Microbe	2019
31375582	Antibody Responses Elicited by Immunization with BG505 Trimer Immune Complexes.	Journal of Virology	2019
29150937	cGMP production and analysis of BG505 SOSIP.664, an extensively glycosylated, trimeric HIV-1 envelope glycoprotein vaccine candidate.	Biotechnol Bioeng	2018